The Influence of Cardiovascular Medications on Iron Metabolism in Patients with Heart Failure
Open Access
Abstract
Background and objectives: The etiology of anemia associated with heart failure is not fully understood, but there are data suggesting the involvement of multiple mechanisms, including various drug therapies used in patients with heart failure. Our primary objective was to evaluate the impact of beta blockers, angiotensin-converting enzyme inhibitors, and calcium-channel blockers on iron metabolism in patients with heart failure. Materials and Methods: This was a prospective observational study that included patients diagnosed with heart failure and iron deficiency (defined by ferritin Results: We found a statistically significant correlation between beta-blocker treatment and ferritin values (p = 0.02). Iron, hemoglobin, and hematocrit levels were significantly lower in the patients using calcium-channel blockers than those who were not. We also found a statistically significant indirect correlation (p = 0.04) between the use of angiotensin-converting enzyme inhibitors and hematocrit levels. Conclusion: The contribution of our study arises from the additional data regarding the drug-induced etiology of iron deficiency. Practitioners should be aware of the potential impact of therapeutic recommendations and this should imply a close monitoring of the biochemical parameters of iron deficiency in this category of patients.Keywords
This publication has 31 references indexed in Scilit:
- Iron Deficiency in Heart Failure: A Practical GuideNutrients, 2013
- Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectivesEuropean Heart Journal, 2012
- Anemia and Mortality in Heart Failure PatientsJACC, 2008
- β blocker treatment is associated with improvement in renal function and anaemia in patients with heart failure: Table 1Heart, 2006
- The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMETEuropean Heart Journal, 2006
- Levels of Hematopoiesis Inhibitor N -Acetyl-Seryl-Aspartyl-Lysyl-Proline Partially Explain the Occurrence of Anemia in Heart FailureCirculation, 2005
- Anemia and Change in Hemoglobin Over Time Related to Mortality and Morbidity in Patients With Chronic Heart FailureCirculation, 2005
- Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunctionJACC, 2005
- Anemia as a risk factor and therapeutic target in heart failureJACC, 2004
- INTERFERENCE OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS ON ERYTHROPOIESIS IN KIDNEY TRANSPLANT RECIPIENTSTransplantation, 1997